{"id":770265,"date":"2025-11-08T21:09:56","date_gmt":"2025-11-08T20:09:56","guid":{"rendered":"https:\/\/www.hashtag.al\/?p=770265"},"modified":"2025-11-08T21:09:56","modified_gmt":"2025-11-08T20:09:56","slug":"pfizer-fiton-betejen-prej-10-miliarde-dollaresh-per-kompanine-metsera-ndersa-novo-nordisk-terhiqet-nga-gara","status":"publish","type":"post","link":"https:\/\/www.hashtag.al\/index.php\/2025\/11\/08\/pfizer-fiton-betejen-prej-10-miliarde-dollaresh-per-kompanine-metsera-ndersa-novo-nordisk-terhiqet-nga-gara\/","title":{"rendered":"Pfizer fiton betej\u00ebn prej 10 miliard\u00eb dollar\u00ebsh p\u00ebr kompanin\u00eb Metsera, nd\u00ebrsa Novo Nordisk t\u00ebrhiqet nga gara","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

\"\"<\/span><\/p>\n

Kompania amerikane e ila\u00e7eve Pfizer<\/em> ka arritur nj\u00eb marr\u00ebveshje prej 10 miliard\u00eb dollar\u00ebsh p\u00ebr t\u00eb bler\u00eb zhvilluesin e barnave kund\u00ebr obezitetit Metsera<\/em>, duke p\u00ebrfunduar nj\u00eb gar\u00eb t\u00eb ashp\u00ebr mes gjigantit farmaceutik me baz\u00eb n\u00eb Nju Jork dhe rivalit danez Novo Nordisk<\/em>.<\/span><\/p>\n

Metsera pranoi ofert\u00ebn e p\u00ebrmir\u00ebsuar t\u00eb Pfizer-it t\u00eb premten n\u00eb mbr\u00ebmje, duke p\u00ebrmendur si arsye rreziqet e mundshme antitrust n\u00eb ofert\u00ebn e Novo Nordisk, t\u00eb cil\u00ebn m\u00eb par\u00eb e kishte cil\u00ebsuar si m\u00eb t\u00eb favorshme.<\/span><\/p>\n

Novo njoftoi t\u00eb shtun\u00ebn se do t\u00eb largohej nga gara, p\u00ebrcjell Reuters.<\/a><\/span><\/span><\/p>\n

Kjo fitore i hap Pfizer-it rrug\u00ebn p\u00ebr t\u00eb hyr\u00eb n\u00eb tregun jasht\u00ebzakonisht fitimprur\u00ebs t\u00eb ila\u00e7eve p\u00ebr humbje peshe, edhe pse produktet e Metsera-s jan\u00eb ende disa vite larg nga tregu.<\/span><\/p>\n

Humbja \u00ebsht\u00eb nj\u00eb goditje p\u00ebr Novo Nordisk, q\u00eb k\u00ebrkon t\u00eb rifitoj\u00eb terrenin e humbur ndaj rivalit amerikan Eli Lilly<\/em>.]<\/span><\/p>\n

 <\/p>\n

Nj\u00eb betej\u00eb e ashp\u00ebr p\u00ebr Metsera<\/span><\/p>\n

Pfizer dukej se e kishte siguruar marr\u00ebveshjen q\u00eb n\u00eb shtator, por nd\u00ebrhyrja e papritur e Novo Nordisk me nj\u00eb ofert\u00eb t\u00eb pad\u00ebshiruar ndezi gar\u00ebn p\u00ebr nj\u00eb aset shum\u00eb t\u00eb k\u00ebrkuar n\u00eb tregun n\u00eb rritje t\u00eb ila\u00e7eve p\u00ebr humbje peshe.<\/span><\/p>\n

Pfizer pranoi t\u00eb paguaj\u00eb 86,25 dollar\u00eb p\u00ebr aksion, me nj\u00eb premium prej 3,69% ndaj mbylljes s\u00eb \u00e7mimit t\u00eb aksioneve t\u00eb premten.<\/span><\/p>\n

Marr\u00ebveshja p\u00ebrfshin 65,60 dollar\u00eb n\u00eb para t\u00eb gatshme dhe nj\u00eb t\u00eb drejt\u00eb shtes\u00eb p\u00ebr pages\u00eb deri n\u00eb 20,65 dollar\u00eb p\u00ebr aksion n\u00eb var\u00ebsi t\u00eb rezultateve t\u00eb ardhshme.<\/span><\/p>\n

Novo Nordisk deklaroi se nuk do t\u00eb rris\u00eb ofert\u00ebn e saj.<\/span><\/p>\n

\u201cPas nj\u00eb procesi konkurrues dhe pas nj\u00eb shqyrtimi t\u00eb kujdessh\u00ebm, Novo Nordisk nuk do t\u00eb rris\u00eb ofert\u00ebn p\u00ebr t\u00eb bler\u00eb Metsera-n,\u201d<\/em> tha kompania daneze.<\/span><\/p>\n

Sipas nj\u00eb burimi pran\u00eb kompanis\u00eb, oferta e fundit e pasuksesshme ishte \u201cvlera maksimale\u201d q\u00eb Novo ishte e gatshme t\u00eb ofronte dhe kompania mbetet e bindur n\u00eb fuqin\u00eb e portofolit t\u00eb saj t\u00eb brendsh\u00ebm p\u00ebr trajtimin e obezitetit.<\/span><\/p>\n

 <\/p>\n

Rreziqe ligjore dhe rregullatore<\/span><\/p>\n

Metsera njoftoi se propozimi i Novo Nordisk paraqiste \u201crreziqe t\u00eb papranueshme ligjore dhe rregullatore\u201d<\/em> n\u00eb krahasim me marr\u00ebveshjen e propozuar me Pfizer, duke p\u00ebrmendur nj\u00eb thirrje nga Komisioni Federal i Tregtis\u00eb (FTC) t\u00eb SHBA-s\u00eb, q\u00eb paralajm\u00ebroi p\u00ebr shkelje t\u00eb mundshme t\u00eb ligjeve antitrust.<\/span><\/p>\n

Novo tha se beson se struktura e ofert\u00ebs s\u00eb saj ishte \u201cn\u00eb p\u00ebrputhje me ligjet antitrust\u201d<\/em>.<\/span><\/p>\n

N\u00eb nj\u00eb deklarat\u00eb, Pfizer u shpreh se ishte e k\u00ebnaqur q\u00eb kishte arritur nj\u00eb marr\u00ebveshje t\u00eb rishikuar me Metsera dhe se pritet ta p\u00ebrmbyll\u00eb bashkimin menj\u00ebher\u00eb pas mbledhjes s\u00eb aksionar\u00ebve t\u00eb kompanis\u00eb m\u00eb 13 n\u00ebntor.<\/span><\/p>\n

 <\/p>\n

\u201cNj\u00eb betej\u00eb n\u00eb stilin e \u2018Game of Thrones\u2019\u201d<\/span><\/p>\n

Sipas analistes s\u00eb Bernstein, Courtney Breen, \u00e7mimi prej 10 miliard\u00eb dollar\u00ebsh bazohet n\u00eb parashikime shum\u00eb optimiste p\u00ebr performanc\u00ebn e ardhshme t\u00eb Metsera-s, duke theksuar se Pfizer do t\u00eb duhet t\u00eb arrij\u00eb 11 miliard\u00eb dollar\u00eb t\u00eb ardhura deri n\u00eb vitin 2040 p\u00ebr ta justifikuar \u00e7mimin.<\/span><\/p>\n

Megjith\u00ebse Metsera aktualisht operon me humbje, bordi i saj rekomandoi q\u00eb aksionar\u00ebt t\u00eb miratojn\u00eb ofert\u00ebn e Pfizer-it. Lufta e ofertave rriti ndjesh\u00ebm vler\u00ebn e aksioneve t\u00eb Metsera-s, t\u00eb cilat u rrit\u00ebn me gati 60% brenda nj\u00eb jave, duke e \u00e7uar vler\u00ebn e tregut n\u00eb 8,75 miliard\u00eb dollar\u00eb.<\/span><\/p>\n

Ish-drejtori i k\u00ebrkimeve dhe zhvillimit t\u00eb Pfizer, John LaMattina, e krahasoi k\u00ebt\u00eb betej\u00eb me blerjen armiq\u00ebsore t\u00eb Warner-Lambert<\/em> n\u00eb vitin 2000, kur Pfizer pagoi 90 miliard\u00eb dollar\u00eb p\u00ebr t\u00eb siguruar kontrollin mbi ila\u00e7in kund\u00ebr kolesterolit Lipitor<\/em>.<\/span><\/p>\n

\u201cEdhe pse kjo \u00ebsht\u00eb nj\u00eb marr\u00ebveshje m\u00eb e vog\u00ebl, Pfizer duhet t\u00eb besoj\u00eb se linja e produkteve t\u00eb Metsera-s \u00ebsht\u00eb thelb\u00ebsore p\u00ebr t\u00eb ardhmen e saj,\u201d<\/em> tha ai.<\/span><\/p>\n

Nj\u00eb nga aksionar\u00ebt kryesor\u00eb t\u00eb Metsera-s, Peter Kolchinsky nga RA Capital, e quajti k\u00ebt\u00eb gar\u00eb nj\u00eb \u201cloj\u00eb t\u00eb stilit Game of Thrones<\/em>\u201d, duke theksuar luft\u00ebn e ashp\u00ebr p\u00ebr kontrollin e kompanis\u00eb.<\/span><\/p>\n

Sipas analistit t\u00eb Leerink Partners<\/em>, David Risinger, dy produktet kryesore eksperimentale t\u00eb Metsera-s, MET-097i (nj\u00eb injektim GLP-1) dhe MET-233i (imitues i hormonit t\u00eb pankreasit amylin), pritet t\u00eb arrijn\u00eb 5 miliard\u00eb dollar\u00eb n\u00eb shitje maksimale t\u00eb kombinuara.<\/span><\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"

Kompania amerikane e ila\u00e7eve Pfizer ka arritur nj\u00eb marr\u00ebveshje prej 10 miliard\u00eb dollar\u00ebsh p\u00ebr t\u00eb bler\u00eb zhvilluesin e barnave kund\u00ebr obezitetit Metsera, duke p\u00ebrfunduar nj\u00eb gar\u00eb t\u00eb ashp\u00ebr mes gjigantit farmaceutik me baz\u00eb n\u00eb Nju Jork dhe rivalit danez Novo Nordisk. Metsera pranoi ofert\u00ebn e p\u00ebrmir\u00ebsuar t\u00eb Pfizer-it t\u00eb premten n\u00eb mbr\u00ebmje, duke p\u00ebrmendur si […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":32,"featured_media":770266,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[53],"tags":[],"class_list":["post-770265","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fast-foodi"],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/posts\/770265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/comments?post=770265"}],"version-history":[{"count":99999,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/posts\/770265\/revisions"}],"predecessor-version":[{"id":770267,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/posts\/770265\/revisions\/770267"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/media\/770266"}],"wp:attachment":[{"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/media?parent=770265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/categories?post=770265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/tags?post=770265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}